CXCR2 and renal cell carcinoma: In addition, increased expression of ELR + CXCL/CXCR2 has been associated with shorter survival in RCC patients [17] and elevated plasmatic CXCL5 and CXCL7 levels correlate with lower sunitinib efficacy in mccRCC [18, 19].